Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes

NCT00102687 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00102687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2005
Completion date
August 1, 2008
Enrollment
151 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes